MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
NASDAQ
0.9812
+0.0574
+6.21%
After Hours: 1.000 +0.019 +1.92% 19:48 03/14 EDT
OPEN
0.9500
PREV CLOSE
0.9238
HIGH
1.040
LOW
0.9309
VOLUME
3.45M
TURNOVER
--
52 WEEK HIGH
3.179
52 WEEK LOW
0.3040
MARKET CAP
204.72M
P/E (TTM)
-1.3172
1D
5D
1M
3M
1Y
5Y
1D
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 4d ago
Weekly Report: what happened at SGMO last week (0303-0307)?
Weekly Report · 5d ago
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/06 22:10
Press Release: Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
Dow Jones · 03/06 21:06
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
Barchart · 03/06 15:05
Wasatch Micro Cap Fund Q4 2024 Commentary
Seeking Alpha · 03/06 02:04
Weekly Report: what happened at SGMO last week (0224-0228)?
Weekly Report · 03/03 09:24
Earnings week ahead: TGT, COST, CRWD, AVGO, JD, PLUG, MRVL, and more
Seeking Alpha · 03/02 13:00
More
About SGMO
More
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
Recently
Symbol
Price
%Change

Webull offers Sangamo Therapeutics Inc stock information, including NASDAQ: SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.